| 000 | 01848 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514180910.0 | ||
| 264 | 0 | _c20040405 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0165-5728 | ||
| 024 | 7 |
_a10.1016/j.jneuroim.2003.12.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFainardi, Enrico | |
| 245 | 0 | 0 |
_aBeneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy. _h[electronic resource] |
| 260 |
_bJournal of neuroimmunology _cMar 2004 |
||
| 300 |
_a206-11 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 |
_aEnzyme-Linked Immunosorbent Assay _xmethods |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHLA Antigens _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon beta-1b |
| 650 | 0 | 4 |
_aInterferon-beta _xtherapeutic use |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xblood |
| 650 | 0 | 4 | _aStatistics, Nonparametric |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aRizzo, Roberta | |
| 700 | 1 | _aMelchiorri, Loredana | |
| 700 | 1 | _aCastellazzi, Massimiliano | |
| 700 | 1 | _aGovoni, Vittorio | |
| 700 | 1 | _aCaniatti, Luisa | |
| 700 | 1 | _aPaolino, Ezio | |
| 700 | 1 | _aTola, Maria Rosaria | |
| 700 | 1 | _aGranieri, Enrico | |
| 700 | 1 | _aBaricordi, Olavio Roberto | |
| 773 | 0 |
_tJournal of neuroimmunology _gvol. 148 _gno. 1-2 _gp. 206-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jneuroim.2003.12.002 _zAvailable from publisher's website |
| 999 |
_c14697222 _d14697222 |
||